Ongoing JV discussions???The first pp involved management. At this time in the process (45% into a pivotal NMIBC Ph. 2, with very promising data so far despite the first 12 patients undertreated, with Rutherrin against NSCLC (#1 killer in US and Canada) and GBM, and with -PHAC-NML having expressed the desire to complete the last preclinical test for a canadian-made anti-COVID-19 vaccine), that was more than a clear signal that they are very comfortable with what they have in hands with this molecule and their scientific platform. Especially considering that they also added more with their own money in May.
The 2nd PP was to close by/around Sept. 14. That it takes more time to close could possibly mean that a big pharma has finally shown interest and is interested to start jv discussions. A dance partner. I've already seen this situation somewhere. And in our case, with Breakthrough designation application getting closer, this could be the time for a big pharma to finally step in, show interest, engage in discussion, before another of its competitors shift them.
We shall see. It could be that, just like it could also simply be a normal delay in the closing of that pp that will resolve soon.
One thing's for sure is that our molecule (TLD-1433), just like our platform (TLC-3000 for oncology and anti-virus) are working. And clearly could allow a big pharma to increase its market shares in some indications.